Filing Details

Accession Number:
0001237899-18-000016
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-09-28 16:35:54
Reporting Period:
2018-09-27
Accepted Time:
2018-09-28 16:35:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1174475 S Michael Brown 777 Old Saw Mill River Road
Tarrytown NY 10591
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-09-27 2,000 $273.67 2,000 No 4 M Direct
Common Stock Disposition 2018-09-27 389 $390.23 1,611 No 4 S Direct
Common Stock Disposition 2018-09-27 601 $391.38 1,010 No 4 S Direct
Common Stock Disposition 2018-09-27 410 $392.37 600 No 4 S Direct
Common Stock Disposition 2018-09-27 300 $393.49 300 No 4 S Direct
Common Stock Disposition 2018-09-27 40 $394.43 260 No 4 S Direct
Common Stock Disposition 2018-09-27 260 $395.42 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2018-09-27 2,000 $0.00 2,000 $273.67
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,750 2024-01-02 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 5,000 Indirect by SLAT
Common Stock 12,349 Indirect by Trust
Footnotes
  1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
  2. Represents volume-weighted average price of sales of 389 shares of Company stock on September 27, 2018 at prices ranging from $390.00 to $390.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
  3. Represents volume-weighted average price of sales of 601 shares of Company stock on September 27, 2018 at prices ranging from $391.00 to $391.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
  4. Represents volume-weighted average price of sales of 410 shares of Company stock on September 27, 2018 at prices ranging from $392.00 to $392.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
  5. Represents volume-weighted average price of sales of 300 shares of Company stock on September 27, 2018 at prices ranging from $393.41 to $393.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
  6. Represents volume-weighted average price of sales of 260 shares of Company stock on September 27, 2018 at prices ranging from $395.18 to $395.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
  7. These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  8. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.